{"id":397209,"date":"2020-12-10T08:03:16","date_gmt":"2020-12-10T13:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397209"},"modified":"2020-12-10T08:03:16","modified_gmt":"2020-12-10T13:03:16","slug":"establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/","title":{"rendered":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <strong>IRB Approval Includes Both the Ergonomix2 Diamond Implant and Mia Tools<\/strong>\n        <\/li>\n<\/ul>\n<p>SANTA BARBARA, Calif., Dec.  10, 2020  (GLOBE NEWSWIRE) &#8212; Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, today announced\u00a0it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia<sup>\u00ae<\/sup> system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond<sup>\u00ae<\/sup> breast implant, and has completed the procedure in the first 21 patients in the study.<\/p>\n<p>\u201cMotiva Mia is truly disruptive to traditional breast aesthetics,\u201d said Dr. Charles Randquist, an internationally recognized plastic surgeon. \u201cMinimally invasive breast enhancement should define a more balanced approach in aesthetics: an augmentation that is considerably more subtle in its sizing and approach and is performed without general anesthesia through a very small incision with a quick recovery and less pain.\u201d<\/p>\n<p>\u201cThe aesthetic results we achieved for these patients exceed today\u2019s standards in plastic surgery,\u201d said Dr. Alexandre Munhoz, professor of plastic surgery at the University of S\u00e3o Paulo School of Medicine. \u201cThese are highly natural, sophisticated outcomes that represent the future of our profession. Just as important as the innovations in the Motiva Ergonomix2 Diamond implant are the tools that make a minimally invasive procedure possible. The innovations and interactions of the implants and tools in Motiva Mia allow for new standards that will change both perceptions and the demand for breast aesthetics.\u201d<\/p>\n<p>\u201cBased on our experience, Motiva Mia enables minimally invasive breast enhancement procedures that address many of the concerns that women have had about traditional breast augmentation surgery,\u201d said Establishment Labs\u2019 founder and chief executive officer, Juan Jos\u00e9 Chac\u00f3n-Quir\u00f3s. \u201cOur third-party commissioned market research suggests that the number of women globally who would consider a minimally invasive procedure could be as many as 1.9 million annually. With Motiva Mia, our intention is to make breast aesthetics far more accessible than it has ever been.<\/p>\n<p>\u201cIt is important to note that we received IRB approval for the Motiva Mia system, which includes both the Ergonomix2 Diamond implant as well as all our proprietary tools that make the minimally invasive procedure possible,\u201d Chac\u00f3n-Quir\u00f3s continued. \u201cThe successful completion of our patient series is an integral part of bringing Motiva Mia to market on an accelerated timeline.\u201d<\/p>\n<p>The Motiva Mia system is designed to offer a minimally invasive breast enhancement procedure in less time and with faster recovery than a traditional breast surgery procedure. The first procedures as part of the Company\u2019s initial cases were performed in Asia beginning in late 2019. In the Costa Rica patient series, Dr. Manuel Chac\u00f3n and Dr. Pablo Sol\u00eds serve as lead plastic surgeons. In addition to this patient series in Costa Rica, the Company also has IRB approval to conduct a separate patient series in Thailand, which it expects to commence in the first quarter of 2021.<\/p>\n<p>\n        <em>The Motiva Mia<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em> system is currently not approved for commercial distribution. Motiva Implants<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em> are undergoing clinical investigation pursuant to U.S. FDA regulations for investigational medical devices. <\/em>\n      <\/p>\n<p>\n        <strong><br \/>\n          <u>About Establishment Labs<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Establishment Labs Holdings Inc.\u00a0(NASDAQ: ESTA) is a global medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants\u00ae, the centerpiece of the MotivaImagine\u00ae\u00a0platform. Motiva Implants\u00ae\u00a0are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company\u2019s direct salesforce. In\u00a0March 2018,\u00a0Establishment Labs\u00a0received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant\u00ae\u00a0clinical trial in\u00a0the United States\u00a0in\u00a0April 2018. In addition to Motiva Implants\u00ae, Establishment Labs\u2019 product and technologies portfolio includes the Divina\u00ae\u00a03D Simulation System and other products and services. Please visit our website for additional information at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yd56pAfpzLkNAfkr_gsZM2eE8zqmREa0Xi57uUcad4JB9uLtKCjWnhnU_DY7tizY2yJpvHdN8gAbA5G4XNn8F-VUQsUlDkozno4Q_fHoI89UQ6lhdAK6sS0wMAyeyiD0ZDBzu7L82lre1a-C3GAeVMc0J7uUG6j2pquF_RnAZ8ah12d9MqdVjgudXK6HmOzzr8p1asW4RIR1cfyFjO9PjrqfPBIDp_MkvJuRvhRlZC6ena3FV4056_MTvebFI5Nj85f5m6g-VSTeO7hPb9CIUQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.establishmentlabs.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Forward-Looking Statements<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). You can find many (but not all) of these statements by looking for words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cwould,\u201d \u201cmay\u201d or other similar expressions in this press release, and includes statements related our ability to commercialize the Motiva Mia<sup>\u00ae<\/sup> system for minimally invasive augmentation including the Motiva Ergonomix2 Diamond<sup>\u00ae<\/sup> breast implant. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the Company\u2019s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the Company\u2019s annual report on Form 10-K filed on March 16, 2020, quarterly reports on Form 10-Q, and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/68bcf427-f2fc-4790-a78b-e90b59d6d020\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor\/Media Contact: \r\nDavid K. Erickson\r\n949-447-6671\r\nderickson@establishmentlabs.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRB Approval Includes Both the Ergonomix2 Diamond Implant and Mia Tools SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, today announced\u00a0it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia\u00ae system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond\u00ae breast implant, and has completed the procedure in the first 21 patients in the study. \u201cMotiva Mia is truly disruptive to traditional breast aesthetics,\u201d said Dr. Charles Randquist, an internationally recognized plastic surgeon. \u201cMinimally invasive breast enhancement should define a more balanced approach in aesthetics: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRB Approval Includes Both the Ergonomix2 Diamond Implant and Mia Tools SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, today announced\u00a0it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia\u00ae system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond\u00ae breast implant, and has completed the procedure in the first 21 patients in the study. \u201cMotiva Mia is truly disruptive to traditional breast aesthetics,\u201d said Dr. Charles Randquist, an internationally recognized plastic surgeon. \u201cMinimally invasive breast enhancement should define a more balanced approach in aesthetics: &hellip; Continue reading &quot;Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T13:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica\",\"datePublished\":\"2020-12-10T13:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/\"},\"wordCount\":1124,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/\",\"name\":\"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\",\"datePublished\":\"2020-12-10T13:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/","og_locale":"en_US","og_type":"article","og_title":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk","og_description":"IRB Approval Includes Both the Ergonomix2 Diamond Implant and Mia Tools SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, today announced\u00a0it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia\u00ae system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond\u00ae breast implant, and has completed the procedure in the first 21 patients in the study. \u201cMotiva Mia is truly disruptive to traditional breast aesthetics,\u201d said Dr. Charles Randquist, an internationally recognized plastic surgeon. \u201cMinimally invasive breast enhancement should define a more balanced approach in aesthetics: &hellip; Continue reading \"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T13:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica","datePublished":"2020-12-10T13:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/"},"wordCount":1124,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/","name":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=","datePublished":"2020-12-10T13:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDAxOCMzODY1MzAxIzIwODc3OTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/establishment-labs-completes-21-motiva-mia-patients-in-irb-approved-study-in-costa-rica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}